Moroctocog alfa Other names: Coagulation factor VIII

Therapeutic indications

Moroctocog alfa is indicated for:

Bleeding in haemophilia A (congenital factor VIII deficiency)

Population group: only adults (18 - 65 years old)

Treatment of bleeding in patients with haemophilia A (congenital factor VIII deficiency).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prophylaxis of bleeding in haemophilia A (congenital factor VIII deficiency)

Population group: only adults (18 - 65 years old)

Prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: REFACTO AF Powder and solvent for solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈